Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Art Bechhoefer who wrote (2756)	10/28/1999 1:57:00 PM
From: celeryroot.com	Respond to of 4676

pls explain what you are talking about.......isip is in fairly good shape for a developing biotec......they have cash to sustain them at current levels for over a year.

To: Art Bechhoefer who wrote (2756)	10/28/1999 2:03:00 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 4676

Art, I'm not seeing the same concern you are. True, they have les qtrs cash reserve than VICL, but it looks like they have 4 qtr's cash. Since they have been able to raise addl funds when needed, and are likely to get milestones from a new partnering, I'm not that worried. Also interest expense if recorded for the 40m load, but payments are deferred 5 years. since the 1st phase was in 97, that gives then the cash for a while longer. IMSCO Scott